ArticleThe European respiratory journal2024
A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing for
Abstract readLetterComment
In one paragraph
Article in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Synergism in drug combination of new tuberculosis antibiotics for drug-resistantMicrobiology spectrum · 2026Article
- We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Performance of a targeted next generation sequencing assay for mycobacterial identification and drug resistance from sputum and isolates.Journal of clinical microbiology · 2026Article
- Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development.The Lancet. Infectious diseases · 2026Review
- Rising bedaquiline resistance: exploring potential causes and next steps.The European respiratory journal · 2026Article
- High efficacy of BPaL among patients infected withIJTLD open · 2026Article
- Bedaquiline resistance in patients with Xpert MTB/RIF Ultra-tested rifampicin-resistant tuberculosis in the Western Cape, South Africa: a prospective study.The Lancet. Microbe · 2026Article
- Quality control and considering systematic MIC shifts are key when evaluating the role ofAntimicrobial agents and chemotherapy · 2025Article
- Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing.Antimicrobial agents and chemotherapy · 2025Article
- High Prevalence of atpE Mutations in Bedaquiline-Resistant Mycobacterium tuberculosis Isolates, Russia.Emerging infectious diseases · 2025Article
- A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.Pathogens & immunity · 2025Review
- Country-level heterogeneity in MDR-TB drug susceptibility supports country-specific policy development.Frontiers in tuberculosis · 2025Article
- Nanopore-based targeted sequencing test for direct tuberculosis identification, genotyping, and detection of drug resistance mutations: a side-by-side comparison of targeted next-generation sequencing technologies.Journal of clinical microbiology · 2024Article
Corrections and comments
- Comment on
Authors and funding
16 authors.
Claudio U KöserDepartment of Genetics, University of Cambridge, Cambridge, UK cuk21@cam.ac.uk.ORCID https://orcid.org/0000-0002-0232-846X
Paolo MiottoEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID https://orcid.org/0000-0003-4610-2427
Nabila IsmailSouth African Medical Research Council (SAMRC) Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID https://orcid.org/0000-0002-2287-1857
Richard M AnthonyNational Tuberculosis Reference Laboratory, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.ORCID https://orcid.org/0000-0002-0550-5273
Christian UtpatelMolecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.
Matthias MerkerEvolution of the Resistome, Research Center Borstel, Borstel, Germany.ORCID https://orcid.org/0000-0003-1386-2331
Stefan NiemannMolecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.ORCID https://orcid.org/0000-0002-6604-0684
Sabira TahseenNational TB Reference Laboratory, National TB Control Program, Islamabad, Pakistan.ORCID https://orcid.org/0000-0002-6887-8149
Leen RigoutsUnit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Camilla RodriguesDepartment of Microbiology, P.D. Hinduja Hospital and Medical Research Centre, Mumbai, India.
Shaheed V OmarCentre for Tuberculosis, National TB Reference Laboratory, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.ORCID https://orcid.org/0000-0001-6983-1636
Maha R FarhatDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-3871-5760
Uladzimir AntonenkaInstitute of Microbiology and Laboratory Medicine, Department IML red GmbH, WHO, Supranational Tuberculosis Reference Laboratory, Gauting, Germany.
Harald HoffmannInstitute of Microbiology and Laboratory Medicine, Department IML red GmbH, WHO, Supranational Tuberculosis Reference Laboratory, Gauting, Germany.ORCID https://orcid.org/0000-0003-4886-5022
Daniela M CirilloEmerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID https://orcid.org/0000-0001-6415-1535
Thomas SchönDepartment of Infectious Diseases, Region Östergötland, Linköping University Hospital, Linköping, Sweden.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antitubercular AgentsDiarylquinolinesMicrobial Sensitivity TestsMycobacterium tuberculosisReference StandardsHumansTuberculosis, Multidrug-ResistantAntitubercular AgentsbedaquilineDiarylquinolines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.